ClinicalTrials.gg
TerminatedNCT03412734Updated Jan 11, 2021Results posted

Vaginal Preparation Prior to Hysterectomy

A Phase 4 interventional study of Chlorhexidine and Iodine in Hysterectomy, sponsored by TriHealth Inc.. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by TriHealth Inc. · Phase 4, Interventional, and Prevention

How we know

Why this study was terminated
The institutional review board recommended the study stop enrollment prior to achieving its initial sample size for patient safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a randomized controlled trial to determine the influence of chlorhexidine gluconate surgical/topical antiseptic solutions on the bacterial environment of the vagina during hysterectomy and compare that to the effect of standard iodine-based preparations on the same.

Read the detailed description

Postoperative infection remains the most common complication of surgical procedures in gynecology. Historically, 30-40% of patients undergoing a hysterectomy develop a post-operative infection. The initiation of antibiotic prophylaxis for appropriate surgical procedures was a significant advancement in the prevention of surgical site infection.

Antibiotic prophylaxis has been standardized and universally implemented. A remaining variable is the method of aseptic preparation of the vagina with substantial variation of technique being reported even within institutions.

The most recent Committee Opinion by the American College of Obstetricians and Gynecologists concludes there is insufficient evidence to render a strong recommendation for either povidone-iodine or chlorhexidine as the ideal agent for surgical preparation of the vagina and that further evidence is necessary.

Povidone-iodine solution has been considered the standard for aseptic surgical preparation of the vagina for decades and is the only solution approved by the FDA for vaginal use. There are however specific qualities of the solution that suggest it may be less than ideal for use in the vagina. More contemporary efforts have begun to focus on chlorhexidine as a more ideal agent for aseptic efforts in surgical preparation of the vagina.

The purpose of our study is to use a randomized controlled trial to determine if chlorhexidine gluconate surgical preparation maintains a lower rate of contamination to the surgical field.

02

Conditions studied

  • Hysterectomy
03

In context

Lead sponsor

TriHealth Inc. is the lead sponsor of 102 studies on the registry; 9 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing total vaginal, laparoscopic assisted vaginal, total laparoscopic, or robotic-assisted laparoscopic hysterectomy by a physician at Cincinnati Urogynecology Associates or Tri-State Gynecology Oncology TriHealth Inc.
  • Concomitant procedures such as vaginal vault suspension, suburethral sling, cystoscopy, enterocele repair, anterior or posterior colporrhaphy, bilateral salpingectomy or salpingooophorectomy, staging procedures, lymph node sampling and other indicated procedures will be included
  • English speaking
  • Ability to provide consent

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to participate in the study
  • Non English speaking
  • Patients that do not undergo a hysterectomy
  • Reported allergy to iodine or chlorhexidine preparation solutions
  • Patients undergoing planned debulking surgery for ovarian, fallopian tube or primary peritoneal cancers
  • Current infection necessitating hysterectomy
  • Active sepsis, pelvic abscess or pelvic inflammatory disease
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Chlorhexidine group

    Drug: Chlorhexidine

  • Active comparator
    Iodine group

    Drug: Iodine

Interventions

  • Chlorhexidine preparation solutions

  • DrugIodine

    Iodine-based preparation solutions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Contamination

    Contamination is defined as having \>5000 bacteria within a culture

    Time frame: 90 minutes from initial preparation

07

Results

Posted Nov 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneChlorhexidine GroupIodine Group
Started4741
Completed4441
Not completed30
Withdrew: Incorrect labeling of samples20
Withdrew: Exclusion criteria - patient receiving flagyl for treatment10

Outcome measures

PrimaryNumber of Participants With Contamination

Contamination is defined as having \>5000 bacteria within a culture

Time frame:
90 minutes from initial preparation
Reported as:
Count of participants · Participants
Number of Participants With Contamination
ParticipantsChlorhexidine GroupIodine Group
Number of Participants With Contamination2035
Statistical analysis
  • Chlorhexidine Group vs Iodine Group · Regression, Logistic · p = <0.001 (p-value is adjusted for baseline BV (Bacterial Vaginosis)) · Odds ratio (or): 10.6 · 95% CI 3.02 to 37.34

Adverse events

Collected over 2 week post-op. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chlorhexidine Group0/44 (0%)0/44 (0%)0/44 (0%)
Iodine Group0/41 (0%)0/41 (0%)0/41 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Chlorhexidine GroupIodine GroupTotal
Mean57.6 ± 10.962.2 ± 11.659.8 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Chlorhexidine GroupIodine GroupTotal
Female444185
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Chlorhexidine GroupIodine GroupTotal
White423981
Black/African American213
Asian011
Region of Enrollment
Region of Enrollment(Participants)Chlorhexidine GroupIodine GroupTotal
United States444185
Bacterial Vaginosis (BV) positive
Bacterial Vaginosis (BV) positive(Participants)Chlorhexidine GroupIodine GroupTotal
Count of participants121830
08

Study locations

1 site
  • Good Samaritan Hospital
    Cincinnati, Ohio 45220, United States
09

References and documents

Publications

  • Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991 Feb;29(2):297-301. doi: 10.1128/jcm.29.2.297-301.1991. PubMed 1706728 ↗
  • Hill AM, Pauls RN, Basil J, Tam T, Yook E, Shatkin-Margolis A, Kleeman S, Yeung J, Aldrich E, Crisp CC. Chlorhexidine Versus Iodine for Vaginal Preparation Before Hysterectomy: A Randomized Clinical Trial. Female Pelvic Med Reconstr Surg. 2022 Feb 1;28(2):77-84. doi: 10.1097/SPV.0000000000001066. PubMed 34333502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Aug 2019, 15 months.

Results were first posted in Nov 2020, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2018
First posted
Jan 26, 2018
StartActual
May 18, 2018
Primary completionActual
Aug 26, 2019
CompletionActual
Jan 29, 2020
Results first posted
Nov 18, 2020
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03412734
Lead sponsor
TriHealth Inc.
Responsible party
Sponsor
First posted
Jan 26, 2018
Start date
May 18, 2018
Primary completion
Aug 26, 2019
Completion
Jan 29, 2020
Results posted
Nov 18, 2020
Last update
Jan 11, 2021

Study contacts

Catrina Crisp, MD
principal investigator · TriHealth - Cincinnati Urogynecology Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chlorhexidine

Start the discussion